

Date: 12/08/2019

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 12th August, 2019

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 12th August, 2019 has approved Unaudited financial results for the quarter ended on 30th June, 2019. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Unaudited Financial results for the quarter ended 30th June, 2019 along with Limited Review Report issued by the Statutory Auditors of the company.

The Meeting started at 5.30 PM and ended at 7.30 PM

Kindly take the above information on record.

Thanking you,

For Vivo Bio Tech Limited



M Kalyan Ram
Whole Time Director
DIN: 02012580

VIVO BIO TECH LIMITED
CIN:L65993TG1987PLC007163


8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate Road no.1, Banjara Hills, Hyderabad 500034

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

Rs. In Lacs

S.No.	PARTICULARS	Consolidated			Standalone			
		QUARTER ENDED		Year Ended	QUARTER ENDED			Year Ended
		30.06.2019	31.03.2019	31.03.2019	30.06.2019	31.03.2019	30.06.2018	31.03.2019
		Un-Audited	Audited	Audited	Un-Audited	Audited	Un - Audited	Audited
I	Revenue from operations	1334.55	1376.50	5583.35	1334.55	1376.50	1358.30	5583.35
II	Other Income	0.00	0.00	1.21	0.00	0.00	0.46	1.21
III	Total Income	1334.55	1376.50	5584.56	1334.55	1376.50	1358.76	5584.56
IV	Expenses							
	a) Increase/(decrease) in stock in trade and WIP	(96.04)	79.31	(65.01)	(96.04)	79.31	(60.41)	(65.01)
	b) Consumption of Raw materials	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Purchase of traded goods	204.40	218.33	1240.92	204.40	218.33	356.60	1240.92
	d) Employees Cost	221.93	300.61	957.80	221.93	300.61	206.77	957.80
	e) Depreciation and amortisation	126.44	126.44	505.77	126.44	126.44	115.98	505.77
	f) Finance Cost	87.48	63.52	264.09	87.48	63.52	66.41	264.09
	g)Administrative Expenditure	626.52	524.30	2119.96	626.52	524.30	493.86	2119.96
	Total	1170.74	1312.51	5023.53	1170.74	1312.51	1179.21	5023.53
V	Profit Before Tax & Exceptional Item (III-IV)	163.81	63.99	561.03	163.81	63.99	179.55	561.03
	Expectional Item	0.00	378.36	378.36	0.00	378.36	0.00	378.36
VI	Profit Before Tax	163.81	(314.37)	182.67	163.81	(314.37)	179.55	182.67
VII	Tax Expense							
	a. Current Tax	63.65	(80.60)	37.60	63.65	(80.60)	34.54	37.60
	b. Deffered tax	(19.98)	63.93	(79.93)	(19.98)	63.93	(4.13)	(79.93)
	Total Tax Expense	43.67	(16.67)	(42.33)	43.67	(16.67)	30.41	(42.33)
VIII	Net Profit After Tax (V-VI)	120.14	(297.70)	225.00	120.14	(297.70)	149.14	225.00
IX	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X	Other Comprehensive Income							
	a.Items that will be reclassified to profit or loss (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total other Comprehensive Income(VII+VIII+IX)	120.14	(297.70)	225.00	120.14	(297.70)	149.14	225.00
XII	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1275.05	1235.05	1235.05	1275.05	1235.05	995.05	1235.05
XIII	Earnings per equity share:							
	1)Basic	0.94	(2.41)	1.82	0.94	(2.41)	1.50	1.82
	2)Diluted	0.94	(2.33)	1.76	0.94	(2.33)	0.67	1.76



Notes

1. The above un-audited financial results for the quarter ended Jun 30, 2019 have been subject to a limited review by the statutory Auditors, are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 12th August,2019.
2. The above un-audited financial results have been prepared in accordance with the IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
4. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 will be published in Newspaper.
5. During the Qtr the company acquired 100% stake in M/s. Donakanti Consulting Services Private Ltd. The Consolidated financial results for the quarter ended June 30, 2019 include the results of the operations of the above entity. The corresponding figures for the prior periods are not comparable
6. Key Standalone information is given below

In Lakhs

Paritculars	Quarter Ended			Year ended
	30-06-2019 Unaudited	31-03-2019 Audited	30-06-2018 UnAudited	31/03/2019 Audited
Revenue From Operations& other income	1334.55	1376.50	1358.76	5583.35
Profit/(Loss)before Tax	163.81	(314.37)	179.55	182.67
Profit/(Loss) after Tax	120.14	(297.70)	149.14	225.00

7. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Place: Hyderabad

Date: 12th August, 2019

For Vivo Bio Tech Limited



M Kalyan Ram
Whole Time Director
DIN: 02012580



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Vivo Bio Tech Limited**

- 1) We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **M/s Vivo Bio Tech Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group'), for the quarter ended June 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

- 4) The Statement includes the results of the following subsidiaries:
- VIVO BIO DISCOVERY SERVICES PRIVATE LIMITED
 - SURLOGIC LIFE CONSULTANCY PRIVATE LIMITED
 - VIVOBIO LABS PRIVATE LIMITED
 - DONAKANTI CONSULTANCY SERVICES PRIVATE LIMITED
- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 (b) above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) The Statement includes the interim financial information of 4 subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (including other income) of Rs. NIL , total net profit after tax of Rs. NIL and total comprehensive income of Rs. NIL for the quarter ended 30 June 2019, respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For P C N & Associates
Chartered Accountants
FRN: 016016S

Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 12-08-2019
UDIN: 19227849AAAAFN7279



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.



Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Vivo Bio Tech Limited

- 1) We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **M/s Vivo Bio Tech Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group'), for the quarter ended June 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

- 4) The Statement includes the results of the following subsidiaries:
- VIVO BIO DISCOVERY SERVICES PRIVATE LIMITED
 - SURLOGIC LIFE CONSULTANCY PRIVATE LIMITED
 - VIVOBIO LABS PRIVATE LIMITED
 - DONAKANTI CONSULTANCY SERVICES PRIVATE LIMITED
- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 (b) above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) The Statement includes the interim financial information of 4 subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (including other income) of Rs. NIL , total net profit after tax of Rs. NIL and total comprehensive income of Rs. NIL for the quarter ended 30 June 2019, respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For P C N & Associates
Chartered Accountants
FRN: 016016S

Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 12-08-2019
UDIN: 19227849AAAAFN7279



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Vivo Bio Tech Limited**

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. **Vivo Bio Tech Limited** for the quarter ended 30th June, 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 12-08-2019
UDIN: 19227849AAAAFM9369



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Vivo Bio Tech Limited

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. **Vivo Bio Tech Limited** for the quarter ended 30th June, 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates
Chartered Accountants
FRN: 016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 12-08-2019
UDIN: 19227849AAAAFM9369